Limax Biosciences

Limax Biosciences is a pioneering biomaterials company leveraging a nature-inspired hydrogel platform to create next-generation tissue adhesives. Founded in 2020 as a spinout from the Wyss Institute at Harvard University, the company is developing HemoMax, a tough, stretchable, and biocompatible adhesive aimed at revolutionizing surgical hemostasis, wound healing, and drug delivery. Positioned in the high-growth biologics and immunology sectors, Limax is targeting significant unmet needs in surgical and wound care with a product that claims performance superior to existing sealants and sutures.

Bioinspired dual polymeric network hydrogel adhesive, modeled after slug mucus, offering robust wet adhesion, high stretchability, rapid action, biocompatibility, and tunability for drug delivery.

Limax competes in the surgical sealants and adhesives market against major medtech companies (e.g., Baxter, J&J, BD) and their fibrin-based, synthetic, and hydrogel products. Its claimed differentiation lies in a unique combination of extreme toughness, wet adhesion, and stretchability not found in current offerings.